Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Sees Significant Increase in Short Interest

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 138,500 shares, a growth of 354.1% from the January 15th total of 30,500 shares. Currently, 7.1% of the company’s shares are short sold. Based on an average daily volume of 4,810,000 shares, the short-interest ratio is currently 0.0 days.

Cyclerion Therapeutics Price Performance

Shares of CYCN traded up $0.18 during midday trading on Wednesday, reaching $3.42. 135,201 shares of the stock were exchanged, compared to its average volume of 4,161,950. The company’s 50 day moving average is $3.44 and its two-hundred day moving average is $2.96. Cyclerion Therapeutics has a 52 week low of $1.27 and a 52 week high of $9.47.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.